Ghada El-Hajj Fuleihan, M.P.H.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Vitamin D | 27 | 2023 | 3223 | 3.780 |
Why?
|
Hypercalcemia | 6 | 2023 | 409 | 3.780 |
Why?
|
Bone Density | 36 | 2023 | 3468 | 3.300 |
Why?
|
Vitamin D Deficiency | 15 | 2023 | 1343 | 3.100 |
Why?
|
Bone Density Conservation Agents | 7 | 2023 | 773 | 2.670 |
Why?
|
Osteoporosis | 16 | 2023 | 1580 | 2.400 |
Why?
|
Cholecalciferol | 8 | 2022 | 537 | 2.230 |
Why?
|
Parathyroid Hormone | 9 | 2022 | 1801 | 2.150 |
Why?
|
Vitamins | 10 | 2023 | 1622 | 1.900 |
Why?
|
Osteoporotic Fractures | 8 | 2020 | 401 | 1.820 |
Why?
|
Absorptiometry, Photon | 18 | 2022 | 1725 | 1.540 |
Why?
|
Hyperparathyroidism, Primary | 2 | 2022 | 160 | 1.380 |
Why?
|
Osteoporosis, Postmenopausal | 6 | 2021 | 386 | 1.370 |
Why?
|
Dietary Supplements | 11 | 2022 | 3297 | 1.370 |
Why?
|
Parathyroidectomy | 4 | 2022 | 235 | 1.250 |
Why?
|
Sarcopenia | 2 | 2022 | 368 | 1.150 |
Why?
|
Lebanon | 11 | 2020 | 229 | 1.140 |
Why?
|
Hip Fractures | 8 | 2019 | 955 | 1.040 |
Why?
|
Hyperparathyroidism | 3 | 2012 | 339 | 0.930 |
Why?
|
Fractures, Bone | 7 | 2022 | 1947 | 0.850 |
Why?
|
Musculoskeletal Development | 2 | 2016 | 14 | 0.840 |
Why?
|
Diphosphonates | 6 | 2023 | 623 | 0.820 |
Why?
|
Puberty | 4 | 2016 | 490 | 0.780 |
Why?
|
Paraneoplastic Syndromes | 1 | 2021 | 151 | 0.720 |
Why?
|
Bone Diseases, Metabolic | 4 | 2011 | 417 | 0.720 |
Why?
|
Overweight | 4 | 2021 | 2371 | 0.710 |
Why?
|
Body Composition | 7 | 2016 | 2401 | 0.630 |
Why?
|
Aromatase Inhibitors | 1 | 2021 | 491 | 0.620 |
Why?
|
Pelvic Bones | 2 | 2017 | 265 | 0.600 |
Why?
|
Bone Remodeling | 6 | 2021 | 575 | 0.600 |
Why?
|
Calcium | 7 | 2022 | 5756 | 0.600 |
Why?
|
Phosphorus | 2 | 2016 | 338 | 0.580 |
Why?
|
Spinal Fractures | 6 | 2016 | 696 | 0.560 |
Why?
|
Alkaline Phosphatase | 3 | 2016 | 865 | 0.550 |
Why?
|
Hypocalcemia | 2 | 2020 | 191 | 0.550 |
Why?
|
Osteocalcin | 1 | 2016 | 273 | 0.540 |
Why?
|
Estrogen Replacement Therapy | 2 | 2015 | 1203 | 0.520 |
Why?
|
Neoplasms | 5 | 2023 | 21683 | 0.510 |
Why?
|
Femur Head | 1 | 2016 | 301 | 0.470 |
Why?
|
Monitoring, Intraoperative | 1 | 2020 | 957 | 0.470 |
Why?
|
Obesity | 6 | 2022 | 12745 | 0.450 |
Why?
|
Anticonvulsants | 3 | 2023 | 1916 | 0.440 |
Why?
|
Humans | 78 | 2023 | 744343 | 0.390 |
Why?
|
Double-Blind Method | 8 | 2022 | 12026 | 0.390 |
Why?
|
Hip Joint | 3 | 2013 | 1002 | 0.380 |
Why?
|
Seizures | 1 | 2023 | 2859 | 0.380 |
Why?
|
Inheritance Patterns | 1 | 2012 | 340 | 0.360 |
Why?
|
Sex Characteristics | 3 | 2016 | 2585 | 0.360 |
Why?
|
Insulin-Like Growth Factor I | 2 | 2016 | 2015 | 0.360 |
Why?
|
Parathyroid Glands | 1 | 2012 | 509 | 0.350 |
Why?
|
Estrogen Receptor alpha | 1 | 2013 | 577 | 0.340 |
Why?
|
Norpregnenes | 1 | 2008 | 7 | 0.340 |
Why?
|
Estrogen Receptor Modulators | 1 | 2008 | 61 | 0.320 |
Why?
|
Musculoskeletal Abnormalities | 1 | 2009 | 95 | 0.320 |
Why?
|
Probability | 1 | 2014 | 2505 | 0.320 |
Why?
|
Female | 46 | 2022 | 380194 | 0.310 |
Why?
|
Bariatric Surgery | 1 | 2017 | 952 | 0.310 |
Why?
|
Insulin Resistance | 2 | 2016 | 3864 | 0.310 |
Why?
|
Estrogens | 1 | 2015 | 1566 | 0.310 |
Why?
|
Diabetes Insipidus, Nephrogenic | 1 | 2007 | 23 | 0.300 |
Why?
|
Anthropometry | 3 | 2011 | 1350 | 0.290 |
Why?
|
Sex Factors | 8 | 2021 | 10397 | 0.290 |
Why?
|
Endocrine System Diseases | 1 | 2009 | 248 | 0.290 |
Why?
|
Lithium Carbonate | 1 | 2007 | 184 | 0.290 |
Why?
|
Aged | 24 | 2023 | 163280 | 0.270 |
Why?
|
Calcium, Dietary | 2 | 2009 | 526 | 0.270 |
Why?
|
Bone and Bones | 3 | 2012 | 2575 | 0.270 |
Why?
|
Rickets | 1 | 2006 | 74 | 0.260 |
Why?
|
Male | 35 | 2022 | 350118 | 0.260 |
Why?
|
Hyperparathyroidism, Secondary | 1 | 2006 | 126 | 0.260 |
Why?
|
Adolescent Nutritional Physiological Phenomena | 1 | 2005 | 63 | 0.250 |
Why?
|
Hydroxycholecalciferols | 2 | 2020 | 44 | 0.250 |
Why?
|
Seasons | 2 | 2021 | 1493 | 0.250 |
Why?
|
Risk Assessment | 9 | 2019 | 23338 | 0.230 |
Why?
|
Accidental Falls | 2 | 2020 | 1062 | 0.230 |
Why?
|
Child Nutritional Physiological Phenomena | 1 | 2005 | 303 | 0.220 |
Why?
|
Kidney Calculi | 1 | 2007 | 465 | 0.220 |
Why?
|
Epilepsy | 2 | 2009 | 3310 | 0.220 |
Why?
|
Life Style | 4 | 2011 | 3835 | 0.210 |
Why?
|
Thinness | 1 | 2006 | 480 | 0.210 |
Why?
|
Bone Diseases | 1 | 2006 | 416 | 0.210 |
Why?
|
Calcium Citrate | 1 | 2021 | 6 | 0.210 |
Why?
|
Diagnosis, Computer-Assisted | 3 | 2011 | 719 | 0.200 |
Why?
|
Femur Neck | 4 | 2014 | 309 | 0.200 |
Why?
|
Premenopause | 2 | 2006 | 1033 | 0.200 |
Why?
|
Child | 17 | 2020 | 77709 | 0.200 |
Why?
|
Nutritional Status | 2 | 2021 | 1609 | 0.200 |
Why?
|
Down Syndrome | 1 | 2009 | 880 | 0.190 |
Why?
|
Adolescent | 16 | 2020 | 85781 | 0.180 |
Why?
|
Reference Values | 4 | 2018 | 4982 | 0.180 |
Why?
|
Organometallic Compounds | 1 | 2004 | 665 | 0.180 |
Why?
|
Albumins | 1 | 2022 | 569 | 0.180 |
Why?
|
United Arab Emirates | 1 | 2019 | 42 | 0.180 |
Why?
|
Asymptomatic Diseases | 1 | 2022 | 551 | 0.170 |
Why?
|
Africa, Northern | 1 | 2019 | 82 | 0.170 |
Why?
|
Densitometry | 1 | 2019 | 156 | 0.170 |
Why?
|
Blood Pressure | 1 | 2015 | 8554 | 0.170 |
Why?
|
Neck Dissection | 1 | 2020 | 197 | 0.170 |
Why?
|
Thiophenes | 1 | 2004 | 588 | 0.170 |
Why?
|
Hematologic Neoplasms | 1 | 2011 | 1832 | 0.170 |
Why?
|
Aged, 80 and over | 11 | 2020 | 57776 | 0.160 |
Why?
|
Aging | 3 | 2023 | 8664 | 0.160 |
Why?
|
Saudi Arabia | 1 | 2019 | 209 | 0.160 |
Why?
|
Body Mass Index | 5 | 2021 | 12720 | 0.160 |
Why?
|
Age Factors | 5 | 2020 | 18370 | 0.160 |
Why?
|
Decision Support Techniques | 1 | 2008 | 1956 | 0.160 |
Why?
|
Adult | 12 | 2023 | 214055 | 0.160 |
Why?
|
Luminescence | 1 | 2018 | 137 | 0.160 |
Why?
|
Femur | 3 | 2013 | 1297 | 0.150 |
Why?
|
Postmenopause | 3 | 2020 | 2461 | 0.150 |
Why?
|
Models, Theoretical | 1 | 2009 | 3589 | 0.150 |
Why?
|
Validation Studies as Topic | 1 | 2017 | 159 | 0.150 |
Why?
|
Teriparatide | 1 | 2019 | 225 | 0.150 |
Why?
|
Vocal Cord Paralysis | 1 | 2020 | 267 | 0.150 |
Why?
|
Meta-Analysis as Topic | 1 | 2022 | 1344 | 0.140 |
Why?
|
Leptin | 1 | 2005 | 1599 | 0.140 |
Why?
|
Follow-Up Studies | 5 | 2021 | 39050 | 0.140 |
Why?
|
Quality of Life | 3 | 2023 | 12804 | 0.140 |
Why?
|
Practice Guidelines as Topic | 2 | 2017 | 7279 | 0.140 |
Why?
|
Latin America | 1 | 2017 | 381 | 0.140 |
Why?
|
Medical Records | 1 | 2002 | 1413 | 0.140 |
Why?
|
Neck | 1 | 2020 | 697 | 0.140 |
Why?
|
Databases, Factual | 4 | 2020 | 7729 | 0.140 |
Why?
|
North America | 2 | 2017 | 1249 | 0.140 |
Why?
|
Chromatography, Liquid | 1 | 2020 | 976 | 0.140 |
Why?
|
Automation | 1 | 2018 | 584 | 0.140 |
Why?
|
Asia | 1 | 2017 | 610 | 0.130 |
Why?
|
Guidelines as Topic | 2 | 2018 | 1405 | 0.130 |
Why?
|
Social Class | 1 | 2004 | 1999 | 0.130 |
Why?
|
Hypopituitarism | 1 | 2017 | 254 | 0.130 |
Why?
|
Calcium-Binding Proteins | 1 | 2020 | 1081 | 0.130 |
Why?
|
Africa | 1 | 2017 | 673 | 0.130 |
Why?
|
Immunoassay | 1 | 2018 | 752 | 0.120 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2018 | 1572 | 0.120 |
Why?
|
Cross-Sectional Studies | 3 | 2023 | 25043 | 0.120 |
Why?
|
Health Care Surveys | 1 | 2002 | 2453 | 0.120 |
Why?
|
Breast Neoplasms | 1 | 2021 | 20822 | 0.120 |
Why?
|
Europe | 2 | 2019 | 3339 | 0.120 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2013 | 15519 | 0.120 |
Why?
|
Tandem Mass Spectrometry | 1 | 2020 | 1157 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 4 | 2022 | 9959 | 0.110 |
Why?
|
Administration, Cutaneous | 1 | 2015 | 711 | 0.110 |
Why?
|
Qualitative Research | 1 | 2021 | 2682 | 0.110 |
Why?
|
Calcium Gluconate | 1 | 2012 | 22 | 0.110 |
Why?
|
Human Growth Hormone | 1 | 2017 | 683 | 0.100 |
Why?
|
Femoral Fractures | 1 | 2016 | 376 | 0.100 |
Why?
|
Ultrasonography | 1 | 2005 | 5985 | 0.100 |
Why?
|
Middle Aged | 13 | 2020 | 213383 | 0.100 |
Why?
|
Societies, Medical | 4 | 2019 | 3743 | 0.100 |
Why?
|
Risk Factors | 10 | 2017 | 72290 | 0.100 |
Why?
|
Nuclear Family | 1 | 2012 | 318 | 0.100 |
Why?
|
Mass Spectrometry | 1 | 2018 | 2203 | 0.100 |
Why?
|
Evidence-Based Medicine | 1 | 2022 | 3610 | 0.090 |
Why?
|
Incidence | 2 | 2019 | 20947 | 0.090 |
Why?
|
Imidazoles | 1 | 2016 | 1206 | 0.090 |
Why?
|
Energy Metabolism | 1 | 2020 | 2899 | 0.080 |
Why?
|
Demography | 1 | 2014 | 1656 | 0.080 |
Why?
|
Lumbar Vertebrae | 2 | 2011 | 1848 | 0.080 |
Why?
|
Multivariate Analysis | 3 | 2008 | 12245 | 0.080 |
Why?
|
Research Design | 2 | 2021 | 5987 | 0.080 |
Why?
|
Ventricular Function, Right | 1 | 2012 | 591 | 0.080 |
Why?
|
Heart Failure | 1 | 2012 | 10900 | 0.080 |
Why?
|
Neoplasm Staging | 1 | 2021 | 11031 | 0.070 |
Why?
|
Health Policy | 1 | 2019 | 2661 | 0.070 |
Why?
|
Postoperative Complications | 2 | 2020 | 15295 | 0.070 |
Why?
|
Osteitis Fibrosa Cystica | 1 | 2006 | 11 | 0.070 |
Why?
|
Treatment Outcome | 5 | 2022 | 63114 | 0.070 |
Why?
|
Myocardial Contraction | 1 | 2012 | 1585 | 0.070 |
Why?
|
Thyroidectomy | 1 | 2012 | 879 | 0.070 |
Why?
|
Solar System | 1 | 2005 | 12 | 0.070 |
Why?
|
Reproducibility of Results | 3 | 2018 | 19905 | 0.070 |
Why?
|
Logistic Models | 2 | 2013 | 13408 | 0.070 |
Why?
|
Epidemiologic Methods | 1 | 2011 | 1364 | 0.070 |
Why?
|
Genotype | 2 | 2013 | 12951 | 0.070 |
Why?
|
Prognosis | 2 | 2021 | 29063 | 0.070 |
Why?
|
Mediterranean Region | 1 | 2005 | 47 | 0.060 |
Why?
|
Thalassemia | 1 | 2006 | 273 | 0.060 |
Why?
|
World Health Organization | 2 | 2008 | 1318 | 0.060 |
Why?
|
Linear Models | 2 | 2006 | 5952 | 0.060 |
Why?
|
Etidronic Acid | 1 | 2004 | 64 | 0.060 |
Why?
|
Methotrexate | 1 | 2011 | 1727 | 0.060 |
Why?
|
Body Weights and Measures | 1 | 2004 | 211 | 0.060 |
Why?
|
Polymerase Chain Reaction | 1 | 2013 | 6171 | 0.060 |
Why?
|
Dexamethasone | 1 | 2011 | 1951 | 0.060 |
Why?
|
Patient Selection | 2 | 2009 | 4215 | 0.060 |
Why?
|
Receptors, Calcitriol | 1 | 2006 | 350 | 0.060 |
Why?
|
Child, Preschool | 2 | 2020 | 41006 | 0.060 |
Why?
|
Mass Screening | 1 | 2019 | 5255 | 0.060 |
Why?
|
Diet Records | 1 | 2005 | 425 | 0.060 |
Why?
|
Long-Term Care | 1 | 2007 | 607 | 0.060 |
Why?
|
Nutritional Requirements | 1 | 2005 | 286 | 0.060 |
Why?
|
Membrane Proteins | 1 | 2020 | 7880 | 0.060 |
Why?
|
Prevalence | 1 | 2020 | 15226 | 0.050 |
Why?
|
Hand Strength | 1 | 2005 | 448 | 0.050 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3133 | 0.050 |
Why?
|
Recombinant Proteins | 1 | 2012 | 6622 | 0.050 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3240 | 0.050 |
Why?
|
Comorbidity | 1 | 2016 | 10388 | 0.050 |
Why?
|
Glucocorticoids | 1 | 2011 | 2107 | 0.050 |
Why?
|
Radius | 1 | 2004 | 422 | 0.050 |
Why?
|
Mothers | 1 | 2012 | 2165 | 0.050 |
Why?
|
Disease Notification | 1 | 2002 | 97 | 0.050 |
Why?
|
Calcium Channel Blockers | 1 | 2004 | 690 | 0.050 |
Why?
|
Physicians | 1 | 2019 | 4567 | 0.050 |
Why?
|
Survival Analysis | 1 | 2014 | 10252 | 0.050 |
Why?
|
Nutrition Policy | 1 | 2005 | 488 | 0.050 |
Why?
|
Diet Surveys | 1 | 2005 | 1173 | 0.050 |
Why?
|
Case-Control Studies | 2 | 2009 | 21746 | 0.050 |
Why?
|
Fractures, Spontaneous | 1 | 2002 | 230 | 0.050 |
Why?
|
Recurrence | 1 | 2012 | 8340 | 0.040 |
Why?
|
Androgen Antagonists | 1 | 2008 | 1377 | 0.040 |
Why?
|
Models, Statistical | 2 | 2011 | 5102 | 0.040 |
Why?
|
Spine | 1 | 2007 | 1144 | 0.040 |
Why?
|
Injections, Intravenous | 1 | 2002 | 1420 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2023 | 11725 | 0.040 |
Why?
|
Ventricular Function, Left | 1 | 2012 | 3670 | 0.040 |
Why?
|
Echocardiography | 1 | 2012 | 5102 | 0.040 |
Why?
|
Placebos | 1 | 2004 | 1676 | 0.040 |
Why?
|
Hormones | 1 | 2023 | 889 | 0.040 |
Why?
|
Stroke Volume | 1 | 2012 | 5007 | 0.040 |
Why?
|
Middle East | 1 | 2019 | 219 | 0.040 |
Why?
|
Developing Countries | 1 | 2010 | 2815 | 0.040 |
Why?
|
Cohort Studies | 2 | 2012 | 40561 | 0.040 |
Why?
|
Infant | 1 | 2020 | 35136 | 0.040 |
Why?
|
Urban Population | 1 | 2006 | 2021 | 0.040 |
Why?
|
Algorithms | 1 | 2017 | 13881 | 0.040 |
Why?
|
Thyroid Gland | 1 | 2023 | 1173 | 0.030 |
Why?
|
Collagen | 1 | 2005 | 2689 | 0.030 |
Why?
|
Regression Analysis | 1 | 2005 | 6459 | 0.030 |
Why?
|
Time Factors | 1 | 2017 | 40075 | 0.030 |
Why?
|
Hypertension | 1 | 2015 | 8480 | 0.030 |
Why?
|
Consensus | 1 | 2023 | 2959 | 0.030 |
Why?
|
Age Determination by Skeleton | 1 | 2014 | 129 | 0.030 |
Why?
|
Young Adult | 1 | 2020 | 56430 | 0.030 |
Why?
|
Kidney Failure, Chronic | 1 | 2006 | 2538 | 0.030 |
Why?
|
Terminology as Topic | 2 | 2014 | 1547 | 0.030 |
Why?
|
Retrospective Studies | 3 | 2009 | 77449 | 0.030 |
Why?
|
Adipose Tissue | 1 | 2004 | 3279 | 0.030 |
Why?
|
Animals | 2 | 2020 | 168757 | 0.030 |
Why?
|
Hormone Replacement Therapy | 1 | 2017 | 745 | 0.030 |
Why?
|
Advisory Committees | 1 | 2016 | 775 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2005 | 7785 | 0.020 |
Why?
|
Calcinosis | 1 | 2019 | 1499 | 0.020 |
Why?
|
Exercise | 1 | 2005 | 5615 | 0.020 |
Why?
|
Schizophrenia | 1 | 2007 | 6882 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2004 | 7913 | 0.020 |
Why?
|
Documentation | 1 | 2014 | 871 | 0.020 |
Why?
|
Body Height | 1 | 2014 | 1577 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2006 | 20129 | 0.010 |
Why?
|
Radiography | 1 | 2011 | 7023 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8388 | 0.010 |
Why?
|
Pediatrics | 1 | 2014 | 3475 | 0.010 |
Why?
|
United States | 1 | 2002 | 69872 | 0.010 |
Why?
|
Risk | 1 | 2004 | 9687 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2004 | 12354 | 0.010 |
Why?
|